Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

BACKGROUND: Sunitinib malate (SUTENT(®)) is an oral, multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib-resistant or – intolerant GIST. The purpose of this study was to explore potential biomarkers of sunitinib pharmacological activity...

詳細記述

保存先:
書誌詳細
主要な著者: DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2007
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1939830/
https://ncbi.nlm.nih.gov/pubmed/17605814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-5-32
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料